Esaote, Hitachi forge ultrasound alliance

Article

Ultrasound developer Esaote, based in Genoa, Italy, has signed a letter of intent for a three-year technical and commercial cooperation agreement with Hitachi Medical. Pending regulatory approvals, the two firms will collaborate on new ultrasound

Ultrasound developer Esaote, based in Genoa, Italy, has signed a letter of intent for a three-year technical and commercial cooperation agreement with Hitachi Medical. Pending regulatory approvals, the two firms will collaborate on new ultrasound products and exchange technical information and components. Each company will continue to independently develop and market its existing product lines.

Both firms highlighted new ultrasound units at December’s RSNA conference. Esaote introduced Technos, a premium ultrasound device designed for abdominal, ob/gyn, vascular, small parts, breast, and urology imaging, while Tarrytown, NY-based Hitachi unveiled Hitachi 6000, a work-in-progress unit that includes tissue harmonic imaging, directional CFA, and artifact suppression algorithms (SCAN 12/15/99 and 1/12/00).

In other Esaote news, the company released preliminary financial results for fiscal year 1999 (end-December), posting consolidated sales of $196.8 million, up 11% from 1998’s $176.2 million. Sales in dedicated MRI climbed more than 60%, from $13.5 million in 1998 to $21.5 million in 1999, while the company’s ultrasound sales were $112.7 million, up from $106.6 million the year before.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.